SCHEMBL16256972

SCHEMBL16256972

CCCCN(C)Cc1cccc2ccccc12

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 4/20 0.71
CYP1A2 P05177 2/20 0.71
CYP2C19 P33261 2/20 0.71
KMT2A Q03164 3/20 0.56
LMNA P02545 4/20 0.52
SLC6A2 P23975 3/20 0.52
SIGMAR1 Q99720 3/20 0.52
NR1I2 O75469 2/20 0.52
HTR2A P28223 2/20 0.52
SLC6A4 P31645 2/20 0.52
KCNH2 Q12809 2/20 0.52
MEN1 O00255 2/20 0.52
ADRA2A P08913 2/20 0.52
DRD2 P14416 1/20 0.52
ADRA2C P18825 1/20 0.52
CNR1 P21554 1/20 0.52
ADRA1A P35348 1/20 0.52
OPRK1 P41145 1/20 0.52
SLC6A3 Q01959 1/20 0.52
EBP Q15125 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11887346 0.91 CYP2D6 (0.79) CYP2D6CYP1A2CYP2C19KMT2ALMNA
SCHEMBL14542581 0.90 CYP2D6 (0.76) CYP2D6CYP1A2CYP2C19KMT2ALMNA
SCHEMBL18714766 0.85 CYP2D6 (0.73) CYP2D6CYP1A2CYP2C19KMT2ALMNA
SCHEMBL10932466 0.84 CYP2D6 (1.00) CYP2D6CYP1A2CYP2C19KMT2ALMNA
SCHEMBL13381683 0.83 CYP2D6 (0.76) CYP2D6CYP1A2CYP2C19KMT2ALMNA
SCHEMBL18085060 0.83 CYP2D6 (0.65) CYP2D6CYP1A2CYP2C19KMT2ALMNA
SCHEMBL11932504 0.83 CYP2D6 (0.65) CYP2D6CYP1A2CYP2C19KMT2ALMNA
SCHEMBL9047389 0.82 CYP2D6 (0.81) CYP2D6CYP1A2CYP2C19KMT2ALMNA
SCHEMBL18137970 0.82 ALDH1A1 (0.50) CYP2D6CYP1A2CYP2C19KMT2ALMNA
SCHEMBL11939041 0.82 HTR1B (0.57) CYP2D6CYP1A2CYP2C19KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160272572-A1 ADENYLYL CYCLASE INHIBITORS FOR NEUROPATHIC AND INFLAMMATORY PAIN PURDUE RESEARCH FOUNDATION 2016-09-22 US disclosed
US-9447122-B2 Arginase inhibitors and methods of use thereof ASTRAZENECA AB (SE) 2016-09-20 US disclosed
US-8894970-B2 Arginase inhibitors and methods of use thereof CORRIDOR PHARMACEUTICALS, INC. (US) 2014-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160272572-A1 ADENYLYL CYCLASE INHIBITORS FOR NEUROPATHIC AND INFLAMMATORY PAIN ADCY1, ADCY2, ADCY5 CYP2D6 4375/4885CYP1A2 4253/4885CYP2C19 4062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.